Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-α and cis-diamminedichloroplatinum

Cancer

Volumn 77, Issue 4, 1996, Pages 725-732

  Uslu, Ruchan ^a   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CDDP; cytotoxicity; free radicals; ovarian carcinoma; resistance; synergy; TNF

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; BUTYLATED HYDROXYANISOLE; CISPLATIN; CYTOTOXIC AGENT; ENZYME INHIBITOR; FREE RADICAL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); TETRAZOLIUM; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; ELECTRON TRANSPORT; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; OVARY CARCINOMA; PRIORITY JOURNAL; RESPIRATORY CHAIN;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BUTYLATED HYDROXYANISOLE; CELL LINE; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; ELECTRON TRANSPORT COMPLEX II; FEMALE; FREE RADICALS; HUMANS; MITOCHONDRIA; MULTIENZYME COMPLEXES; NAD(P)H DEHYDROGENASE (QUINONE); OVARIAN NEOPLASMS; OXAZOLES; OXIDOREDUCTASES; OXYGEN CONSUMPTION; PYRONES; SUCCINATE DEHYDROGENASE; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030021993     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960215)77:4<725::AID-CNCR19>3.0.CO;2-2     Document Type: Article

References (41)

1. Mizutani Y, Bonavida B. Overcoming CDDP resistance of human ovarian tumor cells by combination treatment with CDDP and TNF-α. Cancer 1993;72:809-18.
2. Bonavida B, Tsuchitani T, Zighelboim J, Berek J. Synergy is documented in vitro with low-dose recombinant human tumor necrosis factor, cisplatin, and doxorubucin in ovarian cancer cells. Gynecol Oncol 1990;38:333-9.
3. Mizutani Y, Bonavida B. Overcoming TNF-α and CDDP resistance of a human ovarian cancer cell line (C30) by treatment with buthionine sulfoximine in combination with TNF-α and/or CDDP. Int J Oncol 1993;3:229-35.
4. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
5. Shalaby MR, Palladino MA Jr., Hirabayashi SE, Essalu TE. Lewis GD, Shepard HM, et al. Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J Leukoc Biol 1987;41:196-204.
6. Zimmerman RJ, Marafino BJ Jr., Chan A, Landre P, Winhelke JL. The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factor in vivo. J Immunol 1989;142:1405-9.
7. Schmid DS, Hornung R, McGrath KM, Paul N, Ruddle NH. Target cell DNA fragmentation is mediated by lymphotoxin and TNF. Lymphokine Cytokine Res 1987;6:195-202.
8. Matthews N, Neal ML, Jackson SK, Stark JM. Tumor cell killing by tumor necrosis factor: inhibition of anaerobic conditions, free radical scavengers, and inhibitors of arachidonate metabolism. Immunology 1987;62:153-5.
9. Tsujimoto M, Okamura N, Adachi H. Dexamethasone inhibits the cytotoxic activity of TNF. Biochem Biophys Res Commun 1988;153:104-15.
10. Jones GRN. Free radicals in immunological killing: the case of TNF. Med Hypotheses 1986;21:267-71.
11. Boveris A. Mitochondrial production of superoxide radical and hydrogen peroxide. In: Reivich M, Coburn R, Lahiri S, Chance B, editors. Tissue hypoxia and ischemia. New York: Plenum Press, 1977:67-82.
12. Schulze-Osthoff K, Bakker AC, Vanhaesbroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of TNF is mediated by early damage of mitochondrial functions. J Biol Chem 1992;267(8):5317-23.
13. Schulze-Osthoff K, Beyaert R, Vandervoorde V, Haegeman G, Fiers W. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J 1993; 12(8):3095-3104.
14. Wong GHW, Elwell JH, Oberley WL, Goeddel DV. Manganese superoxide dismutase is essential for cellular resistance to cytotoxicity of TNF. Cell 1989;58:922-31.
15. Timmer-Bosscha H, Mulder NH, deVries EGE. Modulation of CDDP resistance: a review. Br J Cancer 1992;66:227-38.
16. Hanneman J, Baumann K. Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers. Toxicology 1988;51:119-32.
17. Spitz DR, Phillips JW, Adams DT, Sherman CM, Deen DF, Li GC. Cellular resistance to oxidative stress is accompanied by resistance to cisplatin. The significance of increased catalase activity and total glutathione in H202 resistant fibroblasts. J Cell Physiol 1993;156:72-9.
18. Sadzuko Y, Shoji T, Takino Y. Effect of cisplatin on the activities enzymes which protect against lipid peroxidation. Biochem Pharmacol 1992;43:1872-5.
19. Levi J, Jacobs C, Kalman SB, Mctigue M, Weiner MW. Mechanism of cisplatinum nephrotoxicity: I. Effect of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 1988;213:545-50.
20. Rosen M, Figliomeni M, Simpkins H. The interaction of platinum antitumor drugs with mouse liver mitochondria, Int J Exp Pathol 1992;73:61-74.
21. Gordon JA, Gattone VH II. Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 1986; 250:F991-8.
22. Singh G, Maniceia-Bozzo E. Evidence for lack of mitochondrial DNA repair following cis-dichlorodiammine platinum treatment. Cancer Chemother Pharmacol 1990;26:97-100.
23. Kunze B, Jansen R, Pridzuri L, Jurkiewicz E, Hunsmann G, Hofle G, et al. Phenoxan: a new oxazole-pyrone from myxobacteria: production, antimicrobial activity and its inhibition of the electron transport in Complex I of the respiratory chain. J Antibiot 1992;45(9):1549-52.
24. Friedrich T, Van Heek P, Leif H, Ohnishi T, Forche E, Kunze B, et al. Two binding sites of inhibitors in NADH: ubiquinone oxidoreductase (Complex I). Relationship of one site with the ubiquinone-binding site of bacterial glucose: ubiquinone oxidoreductase. Eur J Biochem 1994;219:691-8.
25. Verhagen H, Schilderman PAEL, Kleinjans-Jos CS. Butylated Hydroxyanisole: in perspective. Chem Biol Interact 1991; 80:109-34.
26. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981;35:269-77.
27. Turrens JF, Alexandre A, Lehninger AL. Ubisemiquinone is the electron donor for superoxide formation by Complex III of heart mitochondria. Arch Biochem Biophys 1985;237:408-14.
28. Cino M, Del Maestro RF. Generation of hydrogen peroxide by brain mitochondria: the effect of reoxygenation following postdecapitative ischemia. Arch Biochem Biophys 1989; 269:623-38.
29. Cadenas E, Boveris A. Enhancement of hydrogen peroxide formation by protophores and ionophores in antimycin-supplemented mitochondria. Biochem J 1980;188:431-7.
30. Ferreira J. Effect of BHA on electron transport in rat liver mitochondria. Biochem Pharmacol 1990;40(4):677-84.
31. Aldunate J, Ferreira J, Letelier ME, Repetto Y, Morello A. t-butyl-4-hydroxyanisole, a novel respiratory chain inhibitor. FEBS Lett 1986;195:295-7.
32. Sharma R, Ahmad H, Singhal SS, Saxema M, Srivastava SK, Awasthi YC. Comparative studies on effect of BHA on glutathione and glutathione-s-transferases in the tissues of male and female CD-1 mice. Comp Biochem Physiol [C] 1993; 105(1):31-7.
33. Eaton DL, Harnel DM. Increase in gamma-glutamylcysteine synthetase activity as a mechanism for butylated hydroxyanisole-mediated elevation of hepatic glutathione. Toxicol Appl Pharmacol 1994;126(1):145-9.
34. David M, Horvath G, Schimke I, Mueller MM, Nagy I. Effects of the antioxidant BHA on cytosolic free calcium concentration. Toxicology 1993;77(1-2):115-21.
35. Choi HS, Moore DD. Induction of c-fos and c-jun gene expression by phenolic antioxidants. Mol Endocrinol 1993; 7(12):1596-1602.
36. Clement MV, Stamenkovic I. Fas and tumor necrosis factor-mediated cell death: similarities and distinctions. J Exp Med 1994;180:557-67.
37. Mogil RJ, Shi Y, Bissonnette RP, Bromley P, Yamaguchi I, Green DR. Role of DNA fragmentation in T cell activation-induced apoptosis in vitro and in vivo. J Immunol 1994;152:1674-83.
38. Perez PR, Hamilton TC, Ozols RF, Young RC. Mechanism and modulation of resistance to chemotherapy in ovarian cancer. Cancer 1993;71(Suppl):1571-80.
39. Krosnick JA, Mule JJ, McIntosh JK, Rosenberg SA. Augmentation of antitumor efficacy by the combination of recombinant TNF and chemotherapeutic agents in vivo. Cancer Res 1989;49:3729-33.
40. Morimoto H, Safrit JT, Bonavida B. Synergistic effect of TNF-α and diphtheria-toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol 1991;147:2609-16.
41. Mutch DG, Powell CB, Kao MS, Collins JL In vitro analysis of the anti-cancer potential of tumor necrosis factor in combination with cisplatinum. Gynecol Oncol 1989;34:328-33.